577 related articles for article (PubMed ID: 16740771)
21. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
Edler MC; Buey RM; Gussio R; Marcus AI; Vanderwal CD; Sorensen EJ; Díaz JF; Giannakakou P; Hamel E
Biochemistry; 2005 Aug; 44(34):11525-38. PubMed ID: 16114889
[TBL] [Abstract][Full Text] [Related]
22. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
23. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Naito M; Matsuba Y; Sato S; Hirata H; Tsuruo T
Clin Cancer Res; 2002 Feb; 8(2):582-8. PubMed ID: 11839680
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
25. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
28. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models.
Izbicka E; Campos D; Marty J; Carrizales G; Mangold G; Tolcher A
Anticancer Res; 2006; 26(3A):1983-8. PubMed ID: 16827133
[TBL] [Abstract][Full Text] [Related]
29. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo.
Wang H; Li H; Zuo M; Zhang Y; Liu H; Fang W; Chen X
Cancer Lett; 2008 Sep; 268(1):89-97. PubMed ID: 18482796
[TBL] [Abstract][Full Text] [Related]
30. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
32. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
33. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
34. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
35. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
36. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
37. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
[TBL] [Abstract][Full Text] [Related]
38. Novel C2-C3' N-peptide linked macrocyclic taxoids. Part 2: synthesis and biological activities of docetaxel analogues with a peptide side chain at C2 and their macrocyclic derivatives.
Larroque AL; Dubois J; Thoret S; Aubert G; Chiaroni A; Guéritte F; Guénard D
Bioorg Med Chem; 2007 Jan; 15(1):563-74. PubMed ID: 17064914
[TBL] [Abstract][Full Text] [Related]
39. Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.
Yoo GH; Subramanian G; Piechocki MP; Ensley JF; Kucuk O; Tulunay OE; Lonardo F; Kim H; Won J; Stevens T; Lin HS
Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):735-42. PubMed ID: 18645124
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Miller ML; Roller EE; Zhao RY; Leece BA; Ab O; Baloglu E; Goldmacher VS; Chari RV
J Med Chem; 2004 Sep; 47(20):4802-5. PubMed ID: 15369381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
